2.54
전일 마감가:
$3.06
열려 있는:
$2.9
하루 거래량:
359.61K
Relative Volume:
3.20
시가총액:
$14.96M
수익:
$14.58M
순이익/손실:
$-12.57M
주가수익비율:
-0.4472
EPS:
-5.68
순현금흐름:
$-13.07M
1주 성능:
-15.33%
1개월 성능:
+22.12%
6개월 성능:
-10.56%
1년 성능:
+12.39%
비보스 테라퓨틱스 Stock (VVOS) Company Profile
명칭
Vivos Therapeutics Inc
전화
(866)908-4867
주소
7921 SOUTHPARK PLAZA,, LITTLETON
VVOS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VVOS
Vivos Therapeutics Inc
|
2.54 | 17.67M | 14.58M | -12.57M | -13.07M | -5.68 |
![]()
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
비보스 테라퓨틱스 주식(VVOS)의 최신 뉴스
Vivos Therapeutics’ Earnings Call: Strategic Shifts Amid Financial Challenges - TipRanks
Vivos Therapeutics Shifts Strategy Amid Financial Results - TipRanks
Earnings call transcript: Vivos Therapeutics reports Q1 2025 earnings, stock rises - Investing.com Nigeria
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates - sharewise
Vivos Therapeutics Q1 2025 Financial Results - TradingView
Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update - The Manila Times
Vivos Therapeutics Transforms Business Model with $9M Sleep Center Deal as Product Sales Rise - Stock Titan
Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call - The Manila Times
Vivos Therapeutics, Inc. to Release First Quarter 2025 Financial Results on May 15, 2025 - Nasdaq
Sleep Apnea Tech Leader Vivos Therapeutics Reports Q1 2025 Earnings TomorrowKey Details Here - Stock Titan
Vivos Therapeutics (VVOS) to Release Quarterly Earnings on Tuesday - Defense World
Vivos Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - MSN
Geode Capital Management LLC Grows Stock Holdings in Vivos Therapeutics, Inc. (NASDAQ:VVOS) - Defense World
In brief: Revelstoke recaps AOM, Vivos to make buy, state legislation makes tracks - HME News
Healthcare Stocks Take A Hit Despite Abbott's Earnings Beat - Finimize
Vivos Therapeutics to acquire operating assets of The Sleep Center of Nevada - MSN
Vivos Therapeutics to Acquire The Sleep Center of Nevada - marketscreener.com
Vivos Opens New Sleep Center - Baystreet.ca
Vivos Therapeutics announces agreement to acquire operating assets of SCN - TipRanks
Vivos To Acquire Operating Assets Of The Sleep Center Of Nevada - Nasdaq
Vivos Therapeutics Signs Definitive Agreement To Acquire Largest Sleep Center Operator In Nevada - marketscreener.com
Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada - The Manila Times
Major Healthcare Expansion: Vivos Takes Over Nevada Sleep Giant Serving 3,000 Monthly Patients - Stock Titan
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational Update - MSN
Commonwealth Equity Services LLC Buys 5,000 Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) - Defense World
Positive Sentiment Still Eludes Vivos Therapeutics, Inc. (NASDAQ:VVOS) Following 26% Share Price Slump - simplywall.st
Groundbreaking Collaboration: Vivos Therapeutics and Cellev8 Nutrition Join Forces to Address Sleep Apnea and Oxidative Stress - ACCESS Newswire
Vivos Therapeutics Inc (VVOS) Q4 2024 Earnings Call Highlights: Strategic Shifts Propel Revenue ... By GuruFocus - Investing.com Canada
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vivos Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Vivos Therapeutics’ Earnings Call Highlights Growth and Expansion - TipRanks
Vivos Therapeutics (VVOS) Grows Revenue by 26% and Cuts Operatin - GuruFocus
Vivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global Partners - TipRanks
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Reports Revenue Growth and Strategic Shift - TipRanks
Vivos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Vivos Therapeutics Q4 2024 revenue rises 9% By Investing.com - Investing.com UK
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update - TradingView
Vivos Earnings: Revenue Jumps 9% as FDA Approves Game-Changing Pediatric Sleep Apnea Treatment - Stock Titan
Vivos Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Decline in Short Interest - Defense World
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - The Manila Times
Medical Device Innovator Vivos Sets Key Earnings Date: What to Watch in 2024 Results - Stock Titan
Analyzing Vivos Therapeutics (NASDAQ:VVOS) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
The Silent Epidemic: How Women With Obstructive Sleep Apnea (OSA) Are Often Misdiagnosed - Yahoo Finance
비보스 테라퓨틱스 (VVOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):